Ocuphire Pharma
ref inhibition decreases abnormal angiogenesis | Ocuphire Pharma
Company
Deck Type
Deck date
May 2023
Slide
11 of 27
Similar slides by Ocuphire Pharma
See diffirences between slides (animation)
Investor Presentation
August 2023
history and ref inhibition mechanism | Ocuphire Pharma
Results
January 2023
history and ref inhibition mechanism | Ocuphire Pharma
Results
October 2022
novel and dual acting in an oral pill ref ref | Ocuphire Pharma
Investor Day
January 2022
history and ref inhibition mechanism | Ocuphire Pharma
Related slides by other companies
AstraZeneca
Results
April 2023
rare disease industry leading factor portfolio factor inhibition factor portfolio factor inhibition factor more likely to maintain consistent control than factor inhibitors robust factor portfolio with broad application | AstraZeneca
Equillium
Investor Presentation
November 2023
opportunity in celiac disease | Equillium
Equillium
Investor Presentation
August 2023
opportunity in celiac disease | Equillium
AstraZeneca
Results
November 2024
inflammation modulator cardiorenal disease | AstraZeneca
Other recent decks by Ocuphire Pharma
See all presentations (10 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
Results
January 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io